<div id="readability-page-1"><p>Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) saw an uptick in trading volume on Friday . 2,386,364 shares were traded  during trading, an increase of 191% from the previous session's volume of 820,287 shares.The stock last traded at $97.76 and had previously closed at $99.95.</p><h2>Wall Street Analysts Forecast Growth</h2><p>CRL has been the subject of a number of recent analyst reports. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and dropped their price target for the stock from $190.00 to $170.00 in a research report on Friday, March 21st. William Blair downgraded shares of Charles River Laboratories International from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a report on Wednesday, January 22nd. Redburn Atlantic raised Charles River Laboratories International from a &#34;sell&#34; rating to a &#34;neutral&#34; rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. JPMorgan Chase &amp; Co. dropped their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a &#34;neutral&#34; rating for the company in a research note on Thursday, February 20th. Finally, Citigroup raised Charles River Laboratories International from a &#34;sell&#34; rating to a &#34;neutral&#34; rating and lifted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. One analyst  has rated the stock with a sell rating and sixteen have given a hold rating to the company. Based on data from MarketBeat.com, the stock  has an average rating of &#34;Hold&#34; and a consensus price target of $182.00.</p><p><b>Check Out Our Latest Stock Report on Charles River Laboratories International</b></p><h2>Charles River Laboratories International Stock Down 4.1 %</h2><p>The business's 50 day simple moving average is $157.97 and its 200 day simple moving average is $177.65. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $4.71 billion, a PE ratio of 638.59, a PEG ratio of 4.54 and a beta of 1.45. </p><p>Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the business posted $2.46 earnings per share. The firm's revenue was down 1.1% on a year-over-year basis.  On average, equities research analysts forecast that  Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year. </p><h2>Insider Activity at Charles River Laboratories International</h2><p>In related news, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now directly owns 20,013 shares of the company's stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO James C. Foster bought 6,075 shares of the company's stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by insiders. </p><h2>Institutional Trading of Charles River Laboratories International</h2><p>Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in  Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company's stock worth $1,136,938,000 after buying an additional 60,497 shares during the period.  Wellington Management Group LLP increased its position in shares of  Charles River Laboratories International by 9.0% during the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after acquiring an additional 335,658 shares during the period.  Allspring Global Investments Holdings LLC increased its position in shares of  Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after acquiring an additional 47,221 shares during the period.  Geode Capital Management LLC boosted its holdings in shares of  Charles River Laboratories International by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after purchasing an additional 14,787 shares during the period.  Finally, Ariel Investments LLC grew its stake in  Charles River Laboratories International by 18.9% in the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after purchasing an additional 169,640 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors. </p><h2>Charles River Laboratories International Company Profile</h2> (Get Free Report)<p>Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Charles River Laboratories International</li><li>Investing in Travel Stocks Benefits</li><li>JPMorgan is a Buy, if You Can Handle The Volatility </li><li>What does consumer price index measure? </li><li>United States Steel's Crash: An Unmissable Buying Opportunity</li><li>Using the MarketBeat Dividend Yield Calculator</li><li>Rocket Lab Stock: Weathering the Storm, Time for a Comeback?</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Charles River Laboratories International Right Now?</h2><p>Before you consider Charles River Laboratories International, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.</p><p>While Charles River Laboratories International currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Charles River Laboratories International (NYSE:CRL) experienced a significant increase in trading volume, with 2,386,364 shares traded, up 191% from the previous session. The stock is currently priced at $97.76, down from $99.95. Analysts have mixed ratings, with Goldman Sachs downgrading the stock to 'neutral' and lowering the price target to $170.00. The company reported $2.66 EPS, exceeding estimates, but revenue declined 1.1% year-over-year. Insider trading activity includes a sale by EVP Joseph W. Laplume and a purchase by CEO James C. Foster. Institutional investors have also adjusted their positions in the company.</p>

Charles River Laboratories International (NYSE:CRL) Sees Large Volume Increase - Here's What Happened